Navigation Links
Alseres Pharmaceuticals Enters Agreement to Amend Cethrin(R) License to Lower Milestone Payments and Royalty Rates
Date:5/6/2008

Milestone Payments slated for reduction from $25 Million to $7 Million,

Royalties from 10-12% to 4%

HOPKINTON, Mass., May 6 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE), today announced an agreement with BioAxone Therapeutic, Inc., of Montreal, Canada, whereby, upon payment by Alseres of an option fee of $7 million on or before October 27, 2008, Alseres may exercise an option to amend the Company's Cethrin License Agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Pursuant to the option agreement, the pre-commercial milestone payments in the amended license agreement will be reduced from $25 million to $7 million payable on or before December 31, 2009. In addition, the sales-based royalties in the amended license agreement will be reduced from 10-12% to 4% for spinal cord injury and 1% for all other indications. Finally, the amended license agreement will eliminate all development milestones related to Cethrin.

"This agreement represents a major step forward for Alseres in realizing the full value of our Cethrin spinal cord program and our Rho inhibitor technology platform," stated Peter Savas, Chairman and Chief Executive Officer. "Our strategy for our spinal cord injury program and our other regenerative therapeutics is to demonstrate efficacy in humans and then seek attractive partnerships for the assets. In addition to reducing the future cash burdens of the license, we believe that the reduction in our future royalty obligations will allow us to more freely explore worldwide collaboration and partnership opportunities not only in spinal cord injury b
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
5. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...che- , , MONTVALE, N.J., Nov. 19 /PRNewswir...aq: MEMY ) today announced that it has achieved .../MEM 3454, its lead alpha-7 nicotinic receptor ago...zophrenia (CIAS). The Company has randomized 212 ...illion payment from its partner Roche. Memory Pha...
(Date:11/18/2008)...arn more, make a donation or send a Christmas Seal...e-USNewswire/ -- Millions will receive Christmas S...can Lung Association. These decorative holiday sta...ting back to 1907 when the Lung Association led ef...Americans alive today have no vivid memories of ho...
(Date:11/18/2008)...USNewswire/ -- Forty-two leading U. S. scientists ...rum to consider cutting-edge innovations that may ...y from outbreaks of dangerous zoonotic diseases, t...hose innovations: , , , , A "Do...etects highly contagious and dangerous zoonotic di...
(Date:11/18/2008)...iagnosed, elderly AML patients , , PRINCETO...ticals today announced that the first patient has ...y of CPX-351 (Cytarabine:Daunorubicin) Liposome In...loid leukemia (AML). , , The first patient ...ical College of Cornell University and New York P...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 1Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 2Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 1Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 2Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 1Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 1Concord Grape Juice Has No Significant Impact on Body Weight 3209 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 3
... of market dynamics offers insights into,what will...to,patients, NEW YORK, May 14, 2007 /PRNewswire-US...pment (TB Alliance), a not-for-profit,product dev...d,development of new TB drugs, today released resu...mics of the global TB drug market,that offers a de...
...pitalization and drug withdrawal, CHICAGO, May 15,...migraine patients and physicians commissioned by t...arris Interactive shows that,20 percent of migrain...ive medications that contain barbiturates or opioi... Drug Administration for the,relief of migraines. ...
Other Medicine Technology:New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
(Date:11/21/2008)...apies for preterm labor , , FRIDAY, Nov....und the switch that activates the uterine muscles ...may lead to therapies for preterm labor. , The...IP on the surface of these uterine muscle cells, k..., But researchers from Dartmouth Medical Schoo...
(Date:11/21/2008)...ers to be held on January 8, 2009 , , TORON...ernational Inc. ("MedEmerg") (OTCBB: MDER), one of...nounced today that it has obtained an interim orde...rning its previously announced plan of arrangement...Group Inc. ("AIM") will acquire all of MedEmerg,s ...
(Date:11/21/2008)...niversity of Texas Health Science Center at Housto...n Aging Studies (TEXAS), to promote geriatrics tra...ion award from the Donald W. Reynolds Foundation a...llow us to teach geriatric medicine principles to ...racticing physicians. With the reach of Lyndon B. ...
(Date:11/21/2008)...Newswire-FirstCall/ -- Heska Corporation,(Nasdaq:...ew York Society of,Security Analysts, 12th Annual...ber 2, 2008 at 1177 Avenue of the Americas, 2nd Fl...d to begin at 9:35 a.m. Eastern Time (7:35 a.m.,M...st and for two weeks,following the presentation t...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
...tudy has revealed that anti-depressants like Fluox... damage upon the human skeleton.// The Norwegian U...rcher Bjorn I. Gustafsson has revealed that anti-d...ty of bone building cells, while raising the produ...
...rom University of North Carolina have identified a...ng the activity of Tumor// suppressor protein. Tum...ng the integrity of cell and prevents the cell fro...h of cell. Ack1 is found to be a growth promoting ...
... has lifted the ban on the import of poultry produ... of bird flu strain //for the second time in a mon...n follows identifying that both the isolated virus... is found to be a non-infectious and less pathogen...
...ey has revealed that about 6 out of 10 parents of ...ctivity Disorder (ADHD) are not getting// enough s...launched by the drugs firm Eli Lilly and National ...rmation and Support Service (ADDISS) is to help pa...
Other Medicine News:Health News:Gene responsible for developing prostate cancer identified 2
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: